We are developing two series of small, synthetic molecules. Each series enhances neurotransmission in a different way.
Our 100 Series lead compound, AD101, demonstrated statistically significant improvement in both core symptoms of AD in Placebo-controlled, Double-blind, Phase 2 Proof of Concept Trials. Efficacy was accompanied by a superb profile of safety and tolerability that was not distinguishable from that of the placebo-treated cohort.
100 SERIES – SELECTIVE CaV3.1 AND CaV3.3 T-TYPE
CALCIUM CHANNEL ANTAGONISTS
AD 102 AD 103 AD 104
200 SERIES – CALCIUM / CALMODULIN-DEPENDENT
PROTEIN KINASE II
400 SERIES – NERVE GROWTH FACTOR/ATP
CITRATE LYASE ENHANCERS